NCT06517862View on ClinicalTrials.gov

Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

October 1, 2024

Study Completion Date

December 1, 2024

Conditions
Neonatal Hyperbilirubinemia
Interventions
DRUG

Zinc sulfate

Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.

DRUG

Ursodeoxycholic acid

Neonates will receive oral UDCA solution at 10 mg/day given as 5 mg twice daily.

Trial Locations (1)

Unknown

Neonatal Intensive Care Unit (NICU) of Ain Shams University Hospitals, Cairo

All Listed Sponsors
collaborator

Egyptian Chinese University

OTHER

collaborator

Ain Shams University

OTHER

lead

Amira Adel Fouly

OTHER

NCT06517862 - Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia | Biotech Hunter | Biotech Hunter